Drug Approval | September 16, 2025
Rona submits IND for GalNAc-conjugated siRNA targeting obesity
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
The survey revealed that the proportion of individuals experiencing constant thoughts about food throughout the day declined by 46 percent after starting Wegovy
The discussions are expected to pave the way for the creation of a consolidated national knowledge-sharing platform on IT-enabled Ayush services,
Biocon Foundation is also expanding its reach with this first initiative in Channapatna region
AHLL will become a 100% subsidiary of AHEL with 99.42% held by AHEL and balance in the ESOP pool
The portfolio acquired includes Stugeron brand as well as its leading local brands STUGERON FORTE and STUGERON PLUS across 18 markets in the APAC and EMEA regions
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
The Ma’anshan site approval covers pastilles, oral liquids, and powders
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease
Subscribe To Our Newsletter & Stay Updated
